The addition of pembrolizumab to eribulin does not improve the survival outcomes of patients with hormone receptor-positive, HER2-negative metastatic breast cancer, suggests a phase 2 study.

Phase II study data suggest favorable treatment response and survival with first-line gemcitabine–eribulin in cisplatin-ineligible patients with metastatic urothelial carcinoma.

Combination therapy with the C-X-C chemokine receptor type 4 antagonist balixafortide plus eribulin chemotherapy shows potential in heavily pretreated patients with HER2-negative metastatic breast cancer, phase I study data show.

ESMO 2022 video The current presentation focused on the second interim analysis for OS, which was conducted at a median follow-up of 12.5 months and demonstrated that OS was significantly prolonged for the 272 participants who were randomly allocated to receive sacituzumab govitecan 10 mg/kg on days 1 and 8 of every 21-day cycle compared with the 271 patients who instead received physician’s choice of capecitabine, vinorelbine, gemcitabine, or eribulin.

“ATTAIN had more patients with triple-negative breast cancer (40%) than the BEACON [brain metastases] subgroup (27%), more patients had received prior eribulin-containing regimens (42%vs 24%), and fewer patients had prior [whole-brain radiotherapy] (49% vs 91%),” they write.

The primary endpoint was independently assessed progression-free survival (PFS) in the hormone receptor-positive population, and this was significantly longer for the 331 participants who were randomly assigned to receive T-DXd 5.4 mg/kg every 3 weeks than for their 163 counterparts who instead received physician’s choice of capecitabine, eribulin, gemcitabine, paclitaxel, or nab-paclitaxel.

This was significantly longer than the median duration of 4.0 months for their 271 counterparts who instead received physician’s choice of capecitabine, vinorelbine, gemcitabine, or eribulin.

The phase 3 trial investigators randomly assigned 622 patients from 31 countries who had received one or two prior treatments for metastatic TNBC to receive pembrolizumab 200 mg every 3 weeks for 35 cycles or an investigator’s choice of single-agent chemotherapy, either capecitabine, eribulin, gemcitabine, or vinorelbine.

The 536 trial participants – all of whom had received at least two prior HER2-directed therapies and 1–3 nonhormonal treatments for metastatic disease – were randomly assigned to receive either margetuximab 15 mg/kg or trastuzumab 6 mg/kg (loading dose 8 mg/kg) once every 21 days alongside physician’s choice of capecitabine, eribulin, gemcitabine, or vinorelbine.

Bardia video He said that the ASCENT study was initiated to confirm these results and recruited 529 metastatic TNBC patients (primarily women) who had received at least two lines of chemotherapy, randomly assigning them to receive either intravenous SG 10 mg/kg on days 1 and 8 of every 3-week cycle or physician’s choice of capecitabine, eribulin, vinorelbine, or gemcitabine.

Previously the primary endpoint of progression-free survival in the phase 3 study  found a significant benefit with talazoparib 1 mg/day versus capecitabine, eribulin, gemcitabine, or vinorelbine.

Median PFS was 8.6 months for the 287 patients randomly assigned to receive open-label talazoparib 1 mg/day compared with a median PFS of 5.6 months for the 144 patients who instead received physician’s choice of single-agent therapy with capecitabine, eribulin, gemcitabine, or vinorelbine.

They were compared with 97 patients who were assigned to standard single-agent chemotherapy with the physician’s choice of capecitabine, eribulin, or vinorelbine in 21-day cycles.